title: PREDICTING RESPONSE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION TO BEVACIZUMAB BASED ON SPECTRALIS OPTICAL COHERENCE TOMOGRAPHY.
abstract: OBJECTIVE
  To identify baseline optical coherence tomography factors in exudative age-related macular degeneration that predict response to bevacizumab injections.
  
  
  METHODS
  Patients underwent spectral domain optical coherence tomography at diagnosis and the width, height, area, and location of the subretinal fluid, intraretinal fluid, pigment epithelial detachment, and subretinal tissue were measured. The location and size of photoreceptor and the loss of retinal pigment epithelium were recorded as well as quantitative retinal measurements. Patients received three consecutive monthly injections of bevacizumab after which their best-corrected visual acuity was recorded.
  
  
  RESULTS
  Overall 105 eyes of 105 patients aging 88 ± 8.6 years were included. In univariate correlational analyses, only subretinal fluid width demonstrated a significant positive correlation with improved best-corrected visual acuity (R = 0.230, P = 0.018). Eyes with intraretinal fluid (P = 0.020) and retinal pigment epithelial loss (P = 0.009) located in the subfoveal (as opposed to the juxtafoveal area) demonstrating worst visual outcomes. In stepwise backwards regression, the subretinal fluid width and intraretinal fluid location were the only parameters that remained significant explaining 9.23% of the variation in delta best-corrected visual acuity scores.
  
  
  CONCLUSIONS
  Improvement in best-corrected visual acuity after three injections of bevacizumab can be predicted from optical coherence tomography measurements. Specifically, the authors identified subretinal fluid width and intraretinal fluid location as significant markers.
authors.affiliation: *Department of Ophthalmology, Meir Medical Center, Kfar Sava, Israel; †Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; and ‡Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel.
authors.forename: Ori
authors.initials: O
authors.lastname: Segal
authors.forename: Edward
authors.initials: E
authors.lastname: Barayev
authors.forename: Arie Y
authors.initials: AY
authors.lastname: Nemet
authors.forename: Michael
authors.initials: M
authors.lastname: Mimouni
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D015331:Cohort Studies; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D055213:Retinal Pigment Epithelium / Q000473:pathology; D012189:Retrospective Studies; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab